Shots:

• Codiak to receive up to $72.5M upfront- near-term license payments along with research funding and is eligible to receive development and regulatory milestone payments and tiered royalties on future sales of therapies emerges during the collaboration
• Sarepta gets an exclusive option to license Codiak’s technology to develop and commercialize engineered exosome therapies for up to five neuromuscular targets. Following exercising of an option- Codiak will be responsible for research and preclinical development through IND preparation while Sarepta will lead clinical development and commercial activities
• The collaboration will leverage Codiak’s exosome engineering capabilities with Sarepta’s expertise in precision genetic medicine to develop next-generation therapeutics targeting the needs of patients with neuromuscular diseases

Click here to read full press release/ article | Ref: Sarepta Therapeutics | Image: STAT